Syngen Biotech Co., Ltd. AI Stock Analysis
Syngen Biotech Co., Ltd. (8279) AI Stock Analysis
Syngen Biotech Co., Ltd.
(TPEx:8279)
Syngen Biotech scores in the upper-middle range, driven primarily by a conservative, low-leverage balance sheet and improving free cash flow, paired with an attractive valuation — a 10.7x P/E and a 6.2% dividend yield. The main drag is deteriorating operating performance: TTM revenue has fallen sharply and gross, operating and net margins have compressed materially from their 2021–2022 peaks, pulling return on equity into single digits. Technicals reinforce caution, with the shares trading below their 100- and 200-day averages and momentum indicators sitting in neutral territory. A sustained re-rating would likely require revenue stabilization and a halt to the multi-year margin slide.
Syngen Biotech Co., Ltd. (8279) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.21B
- Dividend Yield
- 6.18%
- Average Volume (3M)
- 41.18K
- Price to Earnings (P/E)
- 10.7
- Beta (1Y)
- 0.20
- Revenue Growth
- -3.92%
- EPS Growth
- -29.93%
- Country
- TW
- Employees
- 554
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Syngen Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1988 and based in Tainan City, Taiwan, Syngen Biotech Co.,Ltd. operates globally, including in Taiwan and China, specializing in the research, development, production, and sale of a diverse array of products. Its core offerings include...
Syngen Biotech Co., Ltd. Financial Statement Overview
Summary
A strong balance sheet (83) and dependable cash generation (78) anchor the profile: debt has been cut to just 0.14x equity, equity funds ~77% of assets, operating cash flow of NT$402M TTM runs near double net income, and free cash flow has rebounded to NT$319M. The offset is a weaker income statement (61) — TTM revenue is down 24.7%, gross margin has slipped from ~36% to 31%, operating margin from ~20% to 12%, and return on equity has fallen to 8.7%. Financially low-risk, but growth and margins are trending the wrong way.
Income Statement
61PositiveBalance Sheet
83Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.05B | 2.14B | 2.01B | 1.84B | 1.93B | 1.47B |
| Gross Profit | 635.67M | 723.59M | 723.94M | 643.92M | 688.15M | 528.34M |
| EBITDA | 305.85M | 448.31M | 423.57M | 442.14M | 448.88M | 380.42M |
| Net Income | 204.72M | 271.59M | 240.21M | 274.83M | 321.24M | 237.77M |
Balance Sheet | ||||||
| Total Assets | 3.14B | 3.05B | 3.08B | 3.11B | 3.07B | 2.42B |
| Cash, Cash Equivalents and Short-Term Investments | 322.49M | 275.46M | 341.93M | 366.89M | 246.05M | 314.80M |
| Total Debt | 338.68M | 315.59M | 544.80M | 681.76M | 786.53M | 236.08M |
| Total Liabilities | 735.85M | 674.89M | 848.52M | 974.63M | 1.08B | 644.16M |
| Stockholders Equity | 2.40B | 2.37B | 2.24B | 2.13B | 1.99B | 1.77B |
Cash Flow | ||||||
| Free Cash Flow | 319.45M | 243.07M | 283.70M | 321.33M | -307.23M | 274.83M |
| Operating Cash Flow | 401.93M | 319.48M | 348.04M | 415.13M | 277.48M | 336.50M |
| Investing Cash Flow | -82.75M | -76.83M | -84.53M | -93.68M | -585.05M | -336.07M |
| Financing Cash Flow | -280.34M | -309.47M | -289.09M | -200.54M | 238.75M | -108.88M |
Syngen Biotech Co., Ltd. Peers Comparison
Overall Rating
TW:843285Outperform- TW:827969Neutral
TW:410847Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:8432 | 85Outperform | TWD 2.36B | 11.30 | ― | 4.22% | 20.56% | 67.85% |
| TW:8279 | 69Neutral | TWD 2.21B | 10.69 | ― | 6.18% | -3.92% | -29.93% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4108 | 47Neutral | TWD 2.06B | -48.44 | ― | ― | 1.10% | 54.83% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:8279 | Syngen Biotech Co., Ltd. | 80.90 | -43.20 | -34.81% | |
| TW:4108 | Phytohealth Corporation | 10.40 | -3.85 | -27.02% | |
| TW:6932 | Merdury Biopharmaceutical Corporation | 5.23 | -5.02 | -48.98% | |
| TW:7731 | MARX Biotech Co., Ltd. | 4.26 | -1.08 | -20.21% | |
| TW:7860 | Teh Seng Pharmaceutical Mfg Co Ltd | 77.80 | 5.13 | 7.07% | |
| TW:8432 | TSH Biopharm Corp. Ltd. | 61.90 | 9.41 | 17.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026